Newsletters - April 1997

Glucosamine sulfate is the preferred form of glucosamine for therapeutic use, mainly as an antiarthritic agent. It is an effective means of providing glucosamine orally and as a building block for the regeneration of cartilage glycosaminoglycans lost during the progression of osteoarthritis.

  1. Glucosamine sulfate occurs naturally in the human body and is almost devoid of toxicity, making it suitable for long-term clinical use1
  2. The chondrometabolic, antireactive and antiarthritis properties of this form have been investigated extensively and are supported by controlled clinical trials2
  3. Pharmacokinetic studies revealed that close to 90% of orally administered glucosamine sulfate is absorbed3
  4. Glucosamine sulfate, in vivo, breaks down into glucosamine and sulfate ions. Glucosamine hydrocholoride, on the other hand, breaks down into glucosamine and free hydrochloric acid. The acid would increase gastric acidity and produce the associated disturbances in vivo
  5. The sulfate ions produced from glucosamine sulfate, on the other hand, participate in chondrometabolic processes. They influence the incorporation of glucosamine and sulfate into the tissues. In a study with gastric mucosal segments, a sulfate content of 300µ mole was found to induce maximum incorporation. Chlorate was found to inhibit glycosylation and induce the formation of low molecular weight mucin polymer. The results of this study revealed that sulfate availability is essential for the formation of high molecular weight mucin polymer. The presence of sulfate ion would therefore enhance the antiarthritic properties of glucosamine

References:

  1. Rovalti, L.C., (1992). Antireactive properties of chondroprotective drugs. Int. J. Tissue Reactions, 14(5), 253-261
  2. Reichelt, A. et al. (1994). Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee, a randomized, placebo-controlled double blind study. Arzneim-Forsch Drug Res. 44(l)(1), 75-80
  3. Setnikar, 1. et al. (1993). Pharmacokinetics of glucosamine in man. Arzneim-Forsch Drug Res. 43(11)(10), 1109-1113
  4. Liau, Y. H. et al. (1992). Role of sulfation in post-translational processing of gastric mucins. Int. J. Riochem. 24(7), 1023-1028

    VISIT US

  • Sabinsa Canada Inc.
    6800 Kitimat Road, Unit 28,
    Mississauga, ON L5N 5M1
    Canada

  • +1 905-286-6616
  • +1 437-988-1663
  • info@sabinsa.ca

CERTIFICATES

Certificate Logos Certificate Logos
Certificate Logos Certificate Logos

CONTACT US

Disclaimer

Please note that this website and information provided herein is not for final consumers of a finished food, beverage, dietary supplement product or cosmetic product, as the information contained herein does not refer to finished products for consumers.

The information provided on the website is intended only for producers of finished food, beverage, dietary supplement and cosmetic product.

The statements related to ingredients on the website, have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

The website and information herein are available in various countries across the world, and hence statements or product information including its classification may not be applicable in your country.

Information and statements provided on the website, shall not be construed as license to practice, or recommendations to infringe, any patents or other intellectual property rights of Sabinsa and others.

By browsing further, You understand the above terms.